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2At a Glance Commentary 
Scientific Knowledge on the Subject: Cardiopulmonary exercise testing (CPET) is a predictor of  
survival in cystic fibrosis, but the evidence is based on studies with small sample sizes that could not 
adjust for important confounders. Moreover, an extensive evaluation of the prognostic utility of various 
CPET parameters and their integration into cluster analysis has not been previously undertaken.
 
What This Study Adds to the Field: This large, international multicenter study extends previous 
knowledge on the prognostic role of traditional CPET parameters and identifies the ventilatory 
equivalent for oxygen (VE/VO2) and carbon dioxide (VE/VCO2) at peak exercise as important 
predictors of the compound outcome survival/lung transplantation (LTx). Using an unbiased, data-
driven clustering approach, we identified a high risk phenotype with poor lung function, nutritional 
status and substantially reduced exercise capacity – a subgroup of patients who may especially benefit 
from regular monitoring of exercise capacity and exercise counselling. 
*Contributors of the Prognostic value of CPET in CF study group
Sibylle Junge, Clinic for Pediatric Pneumology and Neonatology, Hannover Medical School, 
Hannover, Germany
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Abstract
Rationale: The prognostic value of cardiopulmonary exercise testing (CPET) for survival in cystic 
fibrosis (CF) in the context of current clinical management, when controlling for other known 
prognostic factors is unclear. 
Objectives: To determine the prognostic value of CPET-derived measures beyond peak oxygen uptake 
(VO2peak) following rigorous adjustment for other predictors.     
Measurements and Main Results: Data from 10 CF-centers in Australia, Europe and North America 
were collected retrospectively. 510 patients completed a cycle CPET between January 2000 and 
December 2007, of which 433 fulfilled the criteria for a maximal effort. Time to death/lung 
transplantation (LTx) was analyzed using Cox proportional hazards regression. In addition, 
phenotyping using hirarchical Ward’s clustering was performed to characterize high risk subgroups. 
Cox regression showed - even after adjustment for sex, forced expiratory volume in 1s (%predicted), 
body mass index (z-score), age at CPET, Pseudomonas aeruginosa status, and CF-related diabetes as 
covariates in the model - that VO2peak in %predicted, hazard ratio (HR) 0.964 [95%-CI: 0.944-0.986], 
peak work rate (%predicted, HR 0.969 [0.951-0.988], ventilatory equivalent for oxygen (VE/VO2peak) 
HR 1.085 [1.041-1.132], and carbon dioxide (VE/VCO2peak), HR 1.060 [1.007-1.115], all P<0.05) 
were significant predictors of death or LTx at 10 years follow-up. Phenotyping revealed that CPET-
derived measures were important for clustering. We identified a high risk cluster characterized by poor 
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additional prognostic information to established predictors of death/LTx in CF. High risk patients may 
especially benefit from regular monitoring of exercise capacity and exercise counselling.
Abstract Word Count: 250
Keywords: cystic fibrosis, prognosis, survival, peak oxygen uptake, exercise testing, lung 
transplantation
Introduction 
In patients with cystic fibrosis (CF), an increased risk of death has been associated with poor values of 
forced expiratory volume in 1s (FEV1), short stature, low body mass index (BMI), pancreatic 
insufficiency, CF-related diabetes (CFRD), and chronic infection with specific pathogens, e.g., 
Pseudomonas aeruginosa, Burkholderia cepacia or Mycobacteria other than tuberculosis (1-3). 
Several studies have shown that cardiopulmonary exercise testing (CPET) can also provide 
prognostic information in CF with respect to mortality (4-9). Peak oxygen uptake (VO2peak) and 
change in VO2peak over time, peak work rate (Wpeak), the respiratory equivalent for oxygen (minute 
ventilation (VE) divided by VO2) at peak exercise (VE/VO2peak) and the breathing reserve index at the 
ventilatory threshold (VE divided by the estimated maximal voluntary ventilation (MVV)) during an 
incremental cycling test were identified as predictors of death (4-9). 
The analysis of prognostic factors in CF remains a challenge due to its multifactorial 
complexity. Previous studies investigating the association between CPET and survival in CF usually 
considered only a selection of established predictors of mortality and or LTx (e.g., FEV1 and BMI) for 
adjustment in their statistical models. The decision for the choice of covariates for the final 
multivariable models was mostly based on significant univariate associations of single CPET 
parameters. This may, however, overestimate the predictive value of CPET for CF survival as 
numerous other factors are associated with the outcome. 
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Ward’s hierachical clustering – an unbiased, data-driven approach to define clinical/physiological 
phenotypes (10). Such an analysis may help to characterize subgroups with respect to clinical 
characteristics that could be useful for further investigations and/or intervention strategies.  
The primary objective of the present project was to determine the prognostic value of VO2peak 
(primary analysis) and other CPET-derived parameters after rigorous adjustment of a significant 
number of established predictors of mortality in CF that are usually assessed during routine clinical 
assessments in a large multicenter cohort. We further wanted to evaluate whether the importance of 
predictors changes over time using prespecified time periods, i.e., 5, 8, and 10 years after CPET to 
allow comparisons to previous studies (4-7). An additional objective in relation to the study question 
was to examine whether CPET-derived variables were important to define phenotypes that are 
associated with LTx and mortality. 
Methods 
Study design and subjects
For this retrospective study, we analyzed data of patients with CF aged ≥10 years who had a full 
CPET meeting prespecified criteria between 1st January 2000 and 31st December 2007 and for whom 
follow-up information on survival or LTx was available 5 years after CPET. Patients who left their 
respective CF center earlier than 5 years after CPET without information on LTx or subsequent 
survival available were not included in the analysis. Ethical approval was obtained from all respective 
ethical research committees, if required (see online supplementary material). 
Cardiopulmonary exercise testing
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the study period, the first valid test was selected. An overview on equipment and exercise protocols 
used to perform the CPET (Table E1) and criteria for a maximal effort are available in the online 
supplement. 
Statistical analysis 
Data are presented as N (%), mean±SD (ranges) and hazard ratios with 95% confidence 
intervals (CI). Data from lung function testing and CPET was converted to % predicted (11-13). We 
calculated BMI z-scores for children and adolescents (14) and adults (15). The primary composite 
endpoint for survival was LTx and/or death.
The relationship of VO2peak (and Wpeak) with LTx and/or death was visualized by plotting 
survival (Kaplan-Meier curves) of three groups using cut-offs employed by Nixon et al. (4) for Cox 
proportional hazards regression. The Cox proportional hazards assumption was verified graphically 
(log-log plot) and tested using Schoenfeld’s residuals and there was no indication of a violation of this 
assumption. 
First, the association between potential predictors and the compound outcome (death and/or 
LTx) was studied in an univariate analysis using Cox proportional random effects hazards models 
adjusted for clustering on the center level. In a second step, we assessed the prognostic value of CPET-
derived parameters (VO2peak, Wpeak, VEpeak/MVVpred, VE/VO2peak, VE/VCO2peak, SpO2peak, 
and the ∆VE/∆VCO2 slope) in addition to known predictors of survival in CF in multivariable models. 
Cox proportional hazards regression models were performed including FEV1 (% predicted), BMI (z-
score), age at CPET, sex, and the binary coded variables (yes/no) chronic Pseudomonas aeruginosa 
colonization, and CF-related diabetes (CFRD). Exocrine pancreatic insufficiency was a pre-defined 
covariate to be considered for the statistical model. However, since none of the cases (LTx/death) in 
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Consequently, pancreatic insufficiency was not included in the statistical models. Due to the fact that 
data on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) genotype was missing for 
22% of patients with unequal distribution of unavailable/unidentified mutations among cases and 
survivors (52.7% vs. 5.3 %, see Table E2) and there was no significant difference with respect to the 
distribution of mutations between cases and controls for patients in whom the genotype was available, 
we did not consider CFTR genotype as a covariate in the final models. 
The final Cox model analysis was restricted to 10-year follow-up data due to low numbers of 
cases (N=8) from only three study centers with >10-year follow-up data. In addition, we evaluated 
predictors of survival for different time periods (e.g., 5, 8 and 10 years) using Cox models with time-
varying covariates. 
In addition, an unsupervised, data-driven approach was employed to explore the relevance of 
CPET-derived parameters to predict death/LTx in CF patients. Physiological and clinical parameters 
were used as input to define clusters by Ward’s hierarchical clustering (10). The relevance of each 
clustering parameter was investigated using a Forest plot. Based on the results of the Forest plot, the 
parameters for clustering were selected and finally, the association of the identified clusters with LTx 
and/or death using Kaplan-Meier curves was studied. 
All analyses were performed using Stata statistical software version 12 (StataCorp. 2012, 
College Station, Texas, USA and R version 3.0.2 (http://www.R-project.org). A probability for a type I 
error P<0.05 was considered statistically significant. 
Results 
Data from 10 CF centers from Australia, Europe and North America were included in this study. A 
flow chart is shown in figure 1. 433 of 510 CPET’s fulfilled at least one of the four predefined criteria 
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and were, thus, used for the final analysis. Patients with a non-maximal effort during CPET (N=77) 
were younger (13.7±3.5 years, P<0.001), had comparable FEV1 (74.0±21.7 % predicted, P=0.868) and 
showed a trend of lower VO2peak (77.3±18.6 %predicted, P=0.066) compared to the final study 
population. Of 77 excluded patients, 8 (10%) died or had a LTx during the entire follow-up period. We 
noticed differences in deaths/LTx among study centers (Table E3) and consequently adjusted all 
models for study center. Table 1 summarizes patients’ characteristics. Detailed information on patient’s 
clinical characteristics and CPET outcomes separated by study center are shown in Table E3 and E4 in 
the online supplements. 
Survival rates in our study population were 93.1%, 84.7% and 69.3% after 5, 8 and 10 years, 
respectively. Survival probabilities for different VO2peak categories are shown in the Kaplan-Meier 
curve (Figure 2). A figure with Wpeak categories is shown in the online supplement (Figure E1). 
Results of Cox proportional hazard models (univariate and adjusted analyses)
In univariable random effects models with study center adjustment, the CPET-derived information on 
VO2peak, Wpeak, VE/VO2peak, VE/VCO2peak, VEpeak/MVVpred, SpO2peak and the ∆VE/∆VCO2 
slope was each a significant predictor of death or LTx (Table E5). Furthermore, in the complete data 
set, all CPET-derived parameters were significant in the univariable models without study center 
adjustment (crude estimates are shown in Tables E6). A low FEV1 and BMI, as well as chronic 
Pseudomonas aeruginosa colonization were also related to death or LTx (Tables E5-E6). 
A subanalysis restricted to patients with advanced lung disease (FEV1  40% predicted) 
identified age at CPET, VO2peak, Wpeak, VE/VO2peak, and VE/VCO2peak as significant predictors of 
death or LTx (Table E7). Comparable results for CPET-variables were found in non center-adjusted 
analyses (Table E8). 
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parameters and restricted to 2-year follow-up data (n=433 patients with 11 death/LTx cases), VO2peak, 
Wpeak, VE/VO2peak, VE/VCO2peak, VEpeak/MVVpred, and SpO2peak as well as FEV1 and BMI 
were each significantly associated with death or LTx (Tables E9 and E10). Results from these short-
term models were similar to complete dataset models (Tables E5-6), except for a significant effect of 
chronic Pseudomonas aeruginosa colonization on death or LTx (Tables E9-10).
When adjusting the models for sex, age at CPET, FEV1 (% predicted), BMI (z-score), chronic 
Pseudomonas aeruginosa colonization, and CFRD the variables VO2peak, Wpeak, VE/VO2peak and 
VE/VCO2peak remained significant predictors of death or LTx (Table 2). Characteristics of patients 
within the three VO2peak categories are shown in Table E11. Patients in the highest and middle 
VO2peak groups (82% predicted and 59-81% predicted, respectively) had a 72% (HR 0.278, 95% CI 
0.088 to 0.882, P=0.030) and 49% (HR 0.507, 95% CI 0.259 to 0.993, P=0.048) lower risk of dying or 
to receive a lung transplant within the next 10 years compared to patients with a VO2peak of 58% of 
the predicted value. In the model with Wpeak, patients in the highest Wpeak group (92% predicted) 
showed a trend for lower chance for death or LTx (HR 0.417, 95% CI 0.155 to 1.123, P=0.084). 
In the Cox models including time-varying covariates, no effects were observed for different 
predictors of survival for different time periods (e.g., 5, 8 and 10 years, data not shown).
Results of Ward’s hierarchical clustering 
All CPET parameters and FEV1 had a high variable importance to define clusters, as indicated by the 
Forest plot (Figure 3). However, the binary coded variables (sex, chronic Pseudomonas aeruginosa 
infection, pancreatic insufficiency, and CFRD) were less important. Based on the forest plot, the eight 
continuous variables (FEV1, BMI, Wpeak, age at CPET, VO2peak, VEpeak/MVVpred, VE/VO2peak, 
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and VE/VCO2peak) were introduced into the PCA, and five orthogonal factors explained more than 
95% of variance (Table E12). We identified four clusters (Table 3). The prevalence of the primary 
outcome death/LTx during the study period was 2% in cluster 1, 15% in cluster 2, 67% in cluster 3, and 
39% in cluster 4. Cluster 3 was considered a high-risk cluster since the prevalence of the primary 
outcome death/LTx during the ten-year study period (63%) was highest compared to the other three 
clusters (Table 3; Figure 4). This cluster was further characterized by a poor performance for all CPET 
parameters, a high prevalence of Pseudomonas aeruginosa colonization, low BMI z-score, and low 
FEV1 and FVC values (Figure E2). 
We further identified a group of older patients (N=33, cluster 4) with poor lung function, high 
prevalence of chronic Pseudomonas aeruginosa colonization and CFRD, but only a modest reduction in 
BMI and (almost) preserved exercise capacity (Table 3). This group of patients had better survival 
compared to patients belonging to cluster 3. 
Discussion 
Previous studies of the prognostic value of CPET in CF have been limited by small sample sizes that 
could not control for many well-recognized confounding prognostic factors (4-9). The present study 
evaluated a large international sample of patients to examine the utility of CPET parameters in 
predicting survival over the subsequent 10 years. The study confirms the importance of VO2peak and 
Wpeak as key predictors of survival, but also identifies other CPET measures (VE/VO2peak and 
VE/VCO2peak) that may be of great prognostic significance. The use of cluster analysis further 
suggests ´at risk’ phenotypes in whom early recognition, nutritional counselling and exercise 
intervention could be most beneficial.
This is the largest study investigating the prognostic value of CPET-derived parameters in a 
heterogeneous sample of both pediatric and adult patients with CF from Australia, Europe, and North 
America and a follow-up period of up to 14 years. Previous studies investigating the prognostic value 
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of CPET-derived variables in patients with CF were all single-center studies, performed in either 
children (6, 7, 9) and both children and adults (4, 5, 8) with much fewer cases in some studies (9 to 61 
deaths/lung transplants) compared to our study, and also shorter follow-up periods ranging from less 
than 1 year to 8 years (4-9). We extend the current knowledge on the predictive value of CPET-derived 
parameters in addition to established prognostic markers in a large and international cohort and 
identified VE/VO2 and VE/VCO2 as important prognostic factors. 
In our study, patients with the highest VO2peak (82% predicted) had a 72% (HR 0.278, 95% 
CI 0.088 to 0.882) and 49% (HR 0.507, 95% CI 0.259 to 0.993) lower risk of dying or receiving a lung 
transplant in the following 10 years compared to patients in the middle (59 to 81% predicted) and 
lowest VO2peak category (58% predicted), respectively. These findings are in line with a landmark 
single-center study on 109 patients with CF [(age 7-35 years, FEV1 59 % predicted (range 24-95%)] 
demonstrating for the first time, that a high aerobic exercise capacity is associated with lower risk of 
dying over 8 years in CF (4). We confirm the concept and extend these data in a large and international 
sample of pediatric and adult patients with CF treated in the modern era. Indeed, in the study by Nixon 
et al. (4) more than 20 years ago, 8-year survival rates were much lower compared with our study 
population (56% versus 85% survival rate). While survival rates in CF have substantially improved 
over the last decades (16, 17), we also observed an overall higher VO2peak in our study population 
compared to the Nixon study population [(82 % predicted (range 23-151) versus 70 % predicted (range 
21 to 132)] using the same VO2peak prediction equations (4). Our data clearly confirm that a well-
preserved fitness remains important for survival in CF and possibly reflects improvements in treatment 
as well as the change in practice with regard to the acceptance of exercise as a key element in CF 
treatment and a stronger focus on exercise counselling. 
In multivariable models, we identified VO2peak, Wpeak, and VE/VO2 and VE/VCO2 at peak 
exercise as predictors of death/LTx even after rigorous adjustment for established predictors of death in 
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CF (1-3). In our study, age at CPET and FEV1 were significant predictors of death/LTx in all fully 
adjusted models. Lung disease severity, assessed with FEV1, is well known to be a strong predictor of 
survival in CF (18) and whether FEV1 or VO2peak is a stronger predictor of survival in CF is 
controversial (4-6). Most (5-8), but not all studies (4) evaluating the prognostic value of CPET-derived 
parameters showed strong associations of FEV1 with mortality in multivariable models. In our study, 
FEV1 explained the greatest variance of subsequent death/LTx in the adjusted Cox models and FEV1 
was the variable with the highest importance for phenotypic clustering (Figure 3). Interestingly, all 
CPET-related variables (except Wpeak) had a higher importance for the outcome death/LTx than other 
established predictors of survival in CF. This finding supports the conclusion, that CPET-derived 
variables are important prognostic factors in CF. 
Beside VO2peak and Wpeak as know predictors of mortality (4-6, 9), VE/VO2 and VE/VCO2 at 
peak exercise were also associated with death/LTx in our patient population. The VE/VO2peak – a 
marker of ventilatory efficiency at peak exercise - was previously identified as stronger predictor of 
survival than VO2peak in univariate analyses of adult patient data (5). In another study employing 
multivariable analysis in a cohort of 127 children with CF aged 11-14 years (7), the equation to predict 
a higher risk of mortality included VE/VO2peak, BMI and FEV1 (%). These data are supported by our 
cluster analysis (see variable importance plot, Figure 3), indicating that VE/VO2peak has a greater 
importance for phenotype clustering than VO2peak. The highest values for VE/VO2peak and 
VE/VO2peak were observed in the high-risk group (cluster 3, Table 3), which was also the group with 
the lowest FVC that is suggestive of a higher dead space ventilation and reduced breathing reserve (i.e., 
VEpeak/MVVpred was highest in cluster 3). Interestingly, clusters 3 and 4 were both characterized by 
severe lung function impairment, but patients in cluster 3 were younger, had worse nutritional status 
(BMI) and substantially lower exercise capacity, while CFTR genotype showed no obvious differences 
compared to the other clusters (e.g., proportion of patients with severe CFTR mutations). Thus, we can 
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only speculate on underlying reasons such as lower daily physical activity levels, but these data were 
not available. Nevertheless, this cluster of patients may especially benefit from regular monitoring of 
exercise capacity and appropriate exercise counselling to improve nutritional status, one of the key 
predictors of aerobic exercise capacity in CF (19). 
This study has limitations. We included data from 10 CF-centers from different countries with 
likely heterogeneous diagnostic and treatment regimens possibly introducing bias. For these reasons, all 
statistical models were adjusted for study center as random intercept. The models incorporate the fact 
that measurements from the same center are not independent, but more similar to each other by 
assigning an individual intercept for each center. This way, CF care centers with systematically biased 
values (e.g., clearly above or below the average) should not substantially change the overall results. 
A priori, we included data from patients for whom follow-up information on survival and LTx 
was available  5 years after CPET. Thus, patients who left their respective center shortly after the 
CPET were excluded already when the data were collected. This approach might have introduced some 
bias. It is possible that we excluded more healthy and active patients who left their hometown for 
education or work. On the other hand it is also possible that we excluded patients who were not doing 
well and unhappy with their center care. By excluding the few cases on whom follow-up data were not 
available for at least 5 years (n=40), the number of cases available for analysis was somewhat reduced. 
However, since clear information on survival or death/LTx was available on all cases for at least 5 
years, the analyses are more sound. 
Due to a large number of missing data on both CFTR mutations (22 %) and unequal distribution 
among cases and survivors, we were not able to adjust the models for CFTR genotype, a well known 
predictor of survival in CF (20, 21).
The data used for this study were gathered retrospectively. Thus, we had to limit the variables 
used as predictors of prognosis to those that were commonly assessed during the years 2000-2007. 
Page 13 of 53  AJRCCM Articles in Press. Published on 15-October-2018 as 10.1164/rccm.201806-1110OC 
 Copyright © 2018 by the American Thoracic Society 
14
Since for example colonization with Mycobacteria other than tuberculosis or Burkolderia cepacia 
complex was not vigorously assessed at that time, such information could not be included in the 
models. 
It is important to note that transplant predictions (i.e., timing for referral for LTx) are usually 
based on 2-year mortality data in CF (22). Our study was not designed to assess short-term outcomes 
and established predictors of mortality for short-term prediction of mortality such as 6-minute walk test 
distance, and infection with mycobacteria or Burkholderia cepacia complex (22) were not validly 
available in our retrospective data collection. In an exploratory analysis restricted to 2-year follow-up 
data (n=433) which includes only a small number of death/LTx cases (n=11), all CPET parameters 
except the ∆VE/∆VCO2 slope were significantly associated with death/LTx. However, these findings 
must be interpreted with caution and the short-term prognostic value of CPET-derived variables should 
be investigated in a well-designed prospective study including known predictors of referral for LTx 
(22).
Finally, our data were collected before initiation of CFTR modulator therapies. Since these 
drugs may impact on lung function and overall survival, the predictors should be re-evaluated in the 
context of highly effective CFTR modulators that may become available to the majority of CF patients 
in the upcoming years.
As aerobic fitness and ventilatory efficiency measured during CPET are related to prognosis, it 
is important to show whether improvements in these measures would translate into increased survival. 
Several randomized controlled trials have shown that exercise capacity can be increased in CF by 
exercise conditioning programs (23). However, no conditioning studies with survival/mortality being 
the primary outcome are available to date. Since information from exercise testing in CF is relevant to 
patient care in several aspects such as detecting adverse reactions to exercise, understanding exercise 
limitations, guiding a conditioning program, or motivating people to engage in strenuous physical 
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activities, an increasing number of centers are including formal exercise testing in their routine work-
up of patients with CF. By including the information from these tests into patient registries might - in 
the future - allow to determine whether patients who get fitter will benefit with respect to longevity. 
Conclusions
Data collected during CPET such as VO2peak, Wpeak, VE/VO2peak, and VE/VCO2peak provide 
prognostic information in addition to established predictors of death/LTx in CF. Cluster analysis 
revealed that CPET-derived measures were important for phenotyping. The phenotype with the highest 
risk for death/LTx identified by Wards hirachical clustering is characterized by poor lung function, 
nutritional status and exercise capacity and may thus especially benefit from regular monitoring of 
exercise capacity, nutritional counselling, and exercise intervention.
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Figure 1. Flow chart of included patients.
Figure 2. Kaplan-Meier survival curve for three different VO2peak groups. 
Figure 3. Kaplan-Meier survival curve for four different patient groups identified using Ward’s 
hierarchical clustering.
Figure 4. Variable importance plot generated by the unsupervised Random Forest algorithm from the 
12 clinical and physiolgocial parameters used for clustering. Higher values corresponed to higher 
importance of the variable for clustering. BMI, body mass index; CFRD, cystic fibrosis-related 
diabetes; CPET, cardiopulmonary exercise testing; FEV1, forced expiratory volume in 1s; PA, Chronic 
Pseudomonas aeruginosa infection; PI, Pancreatic insufficiency; VEpeak/MVVpred, breathing reserve 
index (MVV was calculated as FEV1*35); VE/VCO2peak, ventilatory equivalent for carbon dioxide; 
VE/VO2peak, ventilatory equivalent for oxygen; VO2peak, peak oxygen consumption; Wpeak, peak 
work rate. 
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Table 1. Patients´ characteristics 
 N=433
Mean Follow-up, all patients (years) 8.9±2.9 (0.1, 14.0)
Mean Follow-Up, survivors (years) 9.6±2.4 (5.0, 14.0)
Mean Follow-up, death or LTx (years) 5.9±3.3 (0.1, 13.5)
Death or LTx, N (%) 74 (17.1)
Age (years) 16.6±6.1 (10.0, 44.5)
Sex, N (% female) 184 (42.5)
BMI (z-score) -0.70±1.0 (-4.53, 1.89)
FEV1 (% predicted) 73.4±21.8 (19.7, 123.4)
Genotype
CFTR, both allels from classes I-III, N (%)* 315 (72.7)
CFTR, at least one allele from classes IV-V, N (%)* 22 (5.1)
CFTR, at least one allele unknown/not available, N (%) 96 (22.2)
Comorbidities
Chronic Pseudomonas aeruginosa infection, N (%) 295/424 (69.6)
Pancreatic insufficiency, N (%) 404/430 (93.3)
CFRD, N (%) 34/426 (8.0)
Exercise capacity
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VO2peak (% predicted) 82.0±21.0 (23.3, 151.2)
Wpeak (% predicted) 91.2±23.2 (17.0, 197.0)
Data are mean±standard deviation (ranges) or number (%) of the study sample. BMI, body mass index; 
CFRD, cystic fibrosis-related diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; 
LTx, lung transplantation; FEV1, forced expiratory volume in 1s; VO2peak, peak oxygen uptake; 
Wpeak, peak work rate. * Information on both CFTR mutations were available for 337 patients. 
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Table 2. Predictors of death or lung transplantation based on random-effects Cox proportional hazards regression (adjusted analyses – 10-year follow-
up). 
CPET-derived variable in the model
VO2peak 
(% pred)
Wpeak 
(% pred)
VE/VO2peak VE/VCO2peak VEpeak/MVVpred SpO2peak 
(%)
∆VE/∆VCO2 
slope
CPET derived 
measure
0.964 (0.944; 
0.986)
P=0.001
0.969 (0.951; 
0.988)
P=0.001
1.085 (1.041; 
1.132)
P<0.001
1.060 (1.007; 
1.115)
P=0.025
0.780 (0.245; 2.547)
P=0.693
0.973 (0.907; 
1.043)
P=0.442
1.020 (0.960; 
1.085)
P=0.521
Additional covariates in the model
Sex 1.813 (1.062; 
3.010)
P=0.029
1.949 (1.1327; 
3.356)
P=0.016
1.651 (0.947; 
2.881)
P=0.077
1.829 (1.060; 
3.158)
P=0.030
1.787 (1.017; 3.318)
P=0.043
1.619 (0.894; 
2.933)
P=0.112
1.724 (0.709; 
4.194)
P=0.230
CFRD 1.877 (0.831; 
4.242)
P=0.130
1.827 (0.802; 
4.159)
P=0.151
2.089 (0.913; 
4.782)
P=0.081
1.864 (0.831; 
3.704)
P=0.145
1.739 (0.778; 3.888)
P=0.177
1.945 (0.830; 
4.557)
P=0.126
2.012 (0.607; 
6.667)
P=0.253
PA 2.624 (0.996 
6.914)
P=0.051
2.928 (1.082; 
7.928)
P=0.034
2.429 (0.884; 
6.675)
P=0.085
2.925 (1.163; 
7.359)
P=0.023
2.842 (1.040; 7.768)
P=0.042
2.778 (0.984; 
7.844)
P=0.054
1.766 (0.521; 
5.988)
P=0.361
Age at CPET 
(years)
0.933 (0.886; 
0.982)
P=0.008
0.940 (0.892; 
0.990)
P=0.019
0.932 (0.879; 
0.989)
P=0.019
0.941 (0.892; 
0.992)
P=0.024
0.924 (0.872; 0.979)
P=0.007
0.938 (0.882; 
0.998)
P=0.045
0.945 (0.858; 
1.042)
P=0.256
FEV1 (% 
predicted)
0.952 (0.932; 
0.973)
P<0.001
0.946 (0.927; 
0.966)
P<0.001
0.928 (0.910; 
0.946)
P<0.001
0.934 (0.918; 
0.951)
P<0.001
0.929 (0.907; 0.950)
P<0.001
0.936 (0.915; 
0.957
P<0.001
0.929 (0.899; 
0.960)
P<0.001
BMI 
(z-score)
1.078 (0.841; 
1.382)
P=0.553
0.991 (0.770; 
1.275)
P=0.942
1.022 (0.781; 
1.338)
P=0.873
1.046 (0.825; 
1.325)
P=0.713
0.958 (0.736; 1.247)
P=0.750
0.968 (0.726; 
1.292)
P=0.828
1.038 (0.714; 
1.510)
P=0.845
Data are hazard ratios (95% confidence interval) and probability of a type I error. BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; 
PA, Pseudomonas aeruginosa; VEpeak/MVVpred, breathing reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for oxygen; 
∆VE/∆VCO2 slope, minute ventilation-carbon dioxide production relationship slope; SpO2peak, oxygen saturation at peak exercise; VO2peak, peak oxygen uptake; Wpeak, peak work 
rate.
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Table 3 Cystic fibrosis risk groups defined by clinical and physiological parameters using Ward`s hierarchical clustering
Cluster 1
N=207
Cluster 2 
N=130
Cluster 3 
N=54
Cluster 4 
N=33
Exposure Variable
Female Sex 85 (41) 55 (42) 28 (52) 11 (33)
Age at CPET (years) 15.91 ± 5.1$ 14.5 ± 3.5+,# 17.1 ± 4.2+,¶ 29.9 ± 6.1$,#,¶
BMI (z-score) -0.17 ± 0.8*†,$ -1.03 ± 0.8*,+ -1.86 ± 1.1†,+,¶ -0.75 ± 0.8$,¶
Genotype**
CFTR, both allels from classes I-III, N (%) 154 (74.4) 97 (74.6) 38 (70.4) 19 (57.6)
CFTR, at least one allele from classes IV-V, 
N (%)
14 (6.8) 6 (4.6) 1 (1.9) 0 (0)
CFTR, at least one allele unknown/not 
available, N (%)
39 (18.8) 27 (20.8) 15 (27.7) 14 (42.4)
CFRD 11 (5)$ 10 (8)# 3 (6)¶ 9 (27)$,#, ¶
Chronic PA colonization 120 (58)*,†,$ 97 (75)* 42 (78)† 30 (91)$
Pancreatic insufficiency 188 (91)*,†,$ 122 (94) * 53 (98)† 32 (97)$
Lung function
FEV1 (% predicted) 87.6 ± 13.2*,†,$ 69.2 ± 16.4*,+,# 43.1 ± 13.9†,+ 49.3 ± 13.9$,#
FVC (% predicted) 95.2 ± 11.1*,†,$ 80.9 ± 12.6*,+,# 60.9 ± 15.2†,+,¶ 71.9 ± 15.6$,#,¶
CPET variables
VO2peak (% predicted) 79.4 ± 16.2*,†,$ 64.8 ± 15.2*,+ 58.8 ± 15.3†,+,¶ 73.4 ± 16.9$,¶
Wpeak (% predicted) 103.9 ± 20.1*,†,$ 83.2 ± 15.4*,+ 66.4 ± 21.3†,+,¶ 84.3 ± 21.1$,¶
VE/VO2peak 37.16 ± 5.6*,† 40.22 ± 6.5*,+ 48.01 ± 8.2†,+,¶ 37.70 ± 6.9¶
VE/VCO2peak 31.75 ± 4.5*,† 34.86 ± 5.3*,+ 41.58 ± 7.7†,+,¶ 32.50 ±  4.2¶
SpO2peak (%) 96.4 ± 3.1†,$ 95.3 ± 3.9+,# 91.5 ± 5.4†,+ 91.1 ± 4.8$,#
VEpeak/MVVpred 0.8 ± 0.2*,†,$ 0.9 ± 0.2*,+ 1.2 ± 0.2†,+,¶ 1.1 ± 0.3$,¶
∆VE/∆VCO2 slope 28.9 ± 4.1*,† 31.4 ± 4.3* 34.4 ± 8.6†,+ 29.4 ± 3.7
Outcomes death or LTx
Up to five years’ follow-up 1 (0)†,$ 4 (3)+ 19 (35)†,+ 4 (12)$
Up to ten years’ follow-up 3 (1)*,†,$ 17 (13) *,+ 34 (63) †,+,¶ 9 (27) $,¶
Entire study period 4 (2)*,†,$ 19 (15) *,+,# 36 (67)†,+ 13 (39) $,#
Data are mean±standard deviation or number (%). BMI, body mass index; CFRD, cystic fibrosis-related diabetes; CFTR, cystic fibrosis 
transmembrane conductance regulator;  CPET, cardiopulmonary exercise test; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; 
SpO2peak, oxygen saturation at peak exercise; VEpeak/MVVpred, breathing reserve index (MVV was calculated as FEV1*35); VE/VCO2peak, 
ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for oxygen; VO2peak, peak oxygen consumption; Wpeak, peak work 
rate. Data for ∆VE/∆VCO2 slope was only available for a subset of patients (cluster 1=119, cluster 2=56, cluster 3=18, and cluster 4=21).
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Differences among clusters were analysed using Chi-squared tests for categorical variables and Kruskal–Wallis, as appropriate. The Bonferroni-
corrected significance level for these tests was 0.008 (overall significance level (0.05) divided by number of tests, which was 6 as we compared 4 
clusters). If the test passed the significance level,  this is indicated by a sign *,†, $, +, #, ¶. ** Differences between clusters based on Chi-squared 
statistics (P=0.039). If Chi-square statistics is calculated for patients with known genotype by excluding patients with at least one “unknown; non-
available” CFTR allele, no difference in genotype is observed between the groups (P=0.338).
* Difference between cluster 1 and 2. 
† Difference between cluster 1 and 3. 
$ Difference between cluster 1 and 4. 
+ Difference between cluster 2 and 3. 
# Difference between cluster 2 and 4.
¶ Difference between cluster 3 and 4.
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Total study sample
N=570
• N = 40 Lost to follow-up.
• N = 18 Missing information regarding
primary endpoint (death/lung
transplantation).
• N = 2 Missing CPET.
Subjects that met 
eligibility criteria
N=510
• N = 77 No valid maximal CPET
according to pre-specified criteria.
Included in 
statistical analysis
N=433
Excluded
Excluded
Figure 1. Flow chart of included 
patients. 
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 Figure 2. Kaplan-Meier survival curve for three different VO2peak groups. 
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 Figure 3. Kaplan-Meier survival curve for four different patient groups identified using Ward’s hierarchical 
clustering. 
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 Figure 4. Variable importance plot generated by the unsupervised Random Forest algorithm from the 12 
clinical and physiolgocial parameters used for clustering. Higher values corresponed to higher importance of 
the variable for clustering. BMI, body mass index; CFRD, cystic fibrosis-related diabetes; CPET, 
cardiopulmonary exercise testing; FEV1, forced expiratory volume in 1s; PA, Chronic Pseudomonas 
aeruginosa infection; PI, Pancreatic insufficiency; VEpeak/MVVpred, breathing reserve index (MVV was 
calculated as FEV1*35); VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory 
equivalent for oxygen; VO2peak, peak oxygen consumption; Wpeak, peak work rate. 
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1ONLINE DATA SUPPLEMENT
Cardiopulmonary exercise testing provides 
additional prognostic information in cystic fibrosis
Helge Hebestreit, Erik H.J. Hulzebos, Jane E. Schneiderman, Chantal Karila, Steven R. Boas, 
Susi Kriemler, Tiffany Dwyer, Margareta Sahlberg, Don S. Urquhart, Larry C. Lands, Felix 
Ratjen, Tim Takken, Liobou Varanistkaya, Viktoria Rücker, Alexandra Hebestreit, Jakob 
Usemann, Thomas Radtke for the Prognostic value of CPET in CF study group 
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Study design and subjects
For this retrospective study, we analyzed data of patients with CF aged ≥10 years who had a full CPET 
meeting prespecified criteria between 1st January 2000 and 31st December 2007 and for whom follow-
up information on survival or LTx was available 5 years after CPET. Patients who left their respective 
CF center earlier than 5 years after CPET without information on LTx or subsequent survival available 
were not included in the analysis.  We searched for publications on exercise testing in CF over the past 
15 years to identify centres performing full CPET in CF using the Godfrey cycle ergometer protocol (1) 
or comparable (e.g., increase in exercise intensity minute-by-minute or as a ramp by 10-25 W/min) 
were identified. Publications on CPET in CF were searched in PubMed between November 2013 to 
February 2014 using the search terms “cardiopulmonary exercise testing” OR “exercise test” AND 
“cystic fibrosis”. Sixteen possibly suitable centers were invited to participate in this study if they could 
provide data of at least 20 patients. Two centers never responded to repeated approaches, and four 
centers could not provide data fulfilling the above criteria.
Genotype classification
Cystic fibrosis transmembrane conductance regulator genotype (CFTR) was classified into five classes 
(27, 28). We grouped patients for descriptive analysis in those with both CFTR alleles in either class I, 
II or III (corresponding to severely reduced CFTR function) and patients with at least one mutant allele 
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publication. We further categorized patients into four CFTR groups: i) F508del homozygous, ii) 
F508del heterozygous, iii) others, and iv) unknown. 
Ethical approval
Ethical approval was obtained from all respective ethical research committees, if required (see online 
supplements). Ethik-Kommission, Institut für Pharmakologie und Toxikologie (No 72/14), Würzburg, 
Wuerzburg, Germany; Medisch Ethische Toetsingscommissie (No 15-268/C), Utrecht, Netherlands; 
AMITA Health Institutional Review Board (#2015-006-03), Glenview, IL, USA; Sydney South West 
Area Health Service (RPAH Zone) Ethics Review Committee (No X14-0227), Sydney, Australia; 
Göteborgs Universitet, Medicinska fakultetens forkningsetikkommitté, Gothenborg, Sweden; Sick Kids 
Research Ethics Board, Toronto, Canada; Research and Development offices at University College 
London, London, UK; Mc Gill University Health Centre, Quebec, Montreal, Canada. For the centers in 
Paris and Switzerland, no ethical approval was required since the retrospective data provided were fully 
anonymized. 
Clinical data
Centers were asked to provide the following data collected at the time of the CPET: age, sex, weight 
and height, pulmonary function, CPET-related data, genetic information, and binary coded CF-related 
comorbidities (exocrine pancreatic insufficiency, CFRD, colonization with Pseudomonas aeruginosa, 
Burkholderia cepacia, Mycobacterium other than tuberculosis), Chronic Pseudomonas aeruginosa 
infection was considered to be present when >50% of at least 4 sputum samples collected in the 
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changed. 
Cardiopulmonary exercise testing 
A valid exercise test with respect to this study was defined as a test with all required data available (see 
below), no equipment failure during the test, and indicators for a maximal effort. These included: i) the 
supervisors impression; ii) a rating of perceived exertion of 9 or 10 on a 0-10 Borg scale or at least 17 
on a 6-20 Borg scale; iii) plateau in VO2 (increase in VO2 during the final completed stage of the test of 
less than 2 mL·kg-1·min-1); iv) a respiratory exchange ratio at peak exercise >1.03 in children or >1.05 
in adults; v) a heart rate at peak exercise exceeding 195 beats.min-1 in children or 209 – 0.86 × age in 
female adults or 207 – 0.78 × age in male adults; vi) VE at peak exercise exceeded estimated MVV 
(FEV1 x 35), also known as breathing reserve index (3, 4). 
The slope of the ∆VE/∆VCO2 -relationship below the respiratory compensation point was 
requested from centers that could access the source data in electronic format. Centers were asked to 
calculate the slope as suggested by Cooper at al. (5). Five centers provided data for the ∆VE/∆VCO2 
slope. 
An overview on equipment and exercise protocols used to perform the CPET is given in Table 
E1.
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Centre name Equipment Test protocol
Chicago/USA Ergometer: 
Lode Excalibur; Groningen, the 
Netherlands
Metabolic Cart: 
ZAN 680, nSpire, Louisville, 
Colorado;
Quark B2 metabolic cart 
(Cosmed, Rome, Italy); 
Sensormedics 229 Breath by 
Breath System, Yorba Linda, 
California
Oxygen saturation:
Masimo RAD7, Irvine, CA, 
USA
Godfrey protocol (6)
Gothenburg Ergometer: 
Electromagnetically braked 
cycle ergometer, Vmax 229 
(Sensor Medics, Yorba 
Linda, CA, USA)
Metabolic Cart: 
Oxygen tension and carbon 
dioxide tension were measured 
using a TCMTM4 radiometer 
(Radiometer, Copenhagen, 
Denmark)
Oxygen saturation:
Pulse oximeter; MasimoSET 
Radical; Masimo Corp, Irvine, 
CA, USA)
Continuous increase in workload 
from 10-30 Watts per min 
depending on last year test. 
London/UK Ergometer:
>128 and <135cm. = Ergoline 
900 (Ergoline, Blitz, Germany); 
Ramp protocol to achieve 8 to 12 
minutes. incremental exercise test.
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(Lode, Groningen, Holland)
Metabolic cart:
MedGraphics
(St Paul, Minnesota, USA).
Cardiac monitoring:       
CardioControl Workstation 
(Welch Allyn, Delft, Holland).
Oxygen saturation: Nonin 
(USA) SpO2 probe placed over 
right supraorbital artery fixed 
with a bandanna
Expected workload of 3Watt/kg 
adjusted dependent upon the 
fitness quartile into which the 
child places themselves, and the 
pre-test spirometry values to attain 
a suitable ramping protocol
Montreal/Canada Ergometer: 
Electronically-braked cycle 
ergometer (Sensormedics)
Metabolic cart:
Vmax, Cardinal Health
Oxygen saturation:
Reflectance probe (Massimo 
forehead probe) for pulse 
oximetry
Godfrey protocol (6) 
Paris/France Ergometer: 
Ergoline: Lode BV, Groningen, 
The Netherlands
Metabolic cart: 
Gould 9000, Sensormedics, 
Dayton, DH
ECG: Marquette Max-1, 
Marquette Electronics
Oxygen saturation: Ohmeda 
3700, Ohmeda, Louisville, CO
Individualized (from the predicted 
VO2peak) incremental in exercise 
intensity (Watt) minute by minute
Switzerland Ergometer: 
Ergoline 800c; (Pilger, St. 
Gallen, Switzerland)
Metabolic cart:
Quark B2 metabolic cart 
(Cosmed, Rome, Italy)
Oxygen saturation:
Nellcor Reflectance oxygen 
sensor RS10 & NPB290, Nellcor 
Pruitan Bennet Inc., Pleasanton, 
CA, USA) 
Godfrey protocol (6)
Stepwise increments depending on 
stature (<120 cm: 10 W/min; 120-
150 cm: 15 W/min; >150 cm: 20 
W/min; FEV1<35%: 10W/min 
irrespective of stature)
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Electronically-braked cycle 
ergometer (Ergometrics 800S, 
SensorMedics, USA); 
Metabolic cart:
Breath-by-breath metabolic cart 
(VMax229, SensorMedics, 
USA); 
Oxygen saturation:
Radical Massimo finger probe 
oximeter for pulse oximetery 
and pulse rate (Massimo 
Corporation, Irvine, USA)
Jones stage 1; stepwise increments 
depending on lung function, 
stature and reported exercise 
tolerance (5-30Watt/increment, 
aiming to reach peak exercise at 8-
10 minutes)
Toronto/Canada Ergometer: 
Lode Corival, Groningen, the 
Netherlands
Metabolic cart: 
Vmax, Cardinal Health, 
Oxygen saturation:
Reflectance probe (Massimo, 
forehead site) for pulse 
oximetry.
Godfrey Protocol (6)
Utrecht/Netherlands Ergometer: 
Lode Corival, Groningen, the 
Netherlands
Metabolic cart: 
Jaeger Oxycon (Germany)
Oxygen saturation:
Nellcor forehead sensor for 
pulse oximetry.
Godfrey Protocol (6)
Würzburg/Germany Ergometer:
Monark 834 E Ergomedic 
ergometer (Varberg, Sweden)
Metabolic cart:
CPX/D metabolic cart 
(MedGraphics, St Paul, MN)
Oxygen saturation:
Nelcor forehead sensor for pulse 
oximetry
Godfrey protocol (6) 
Stepwise increments depending on 
stature (<120 cm: 10 W/min; 120-
150 cm: 15 W/min; >150 cm: 20 
W/min; FEV1<35%: 10W/min 
irrespective of stature)
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Statistical analyses
Cluster analysis methodology
An unsupervised, data-driven approach was used to explore the relevance of CPET-derived parameters 
to predict survival in CF patients. The following twelve parameters were investigated as input to 
perform Ward’s hierarchical clustering with the software R version 3.0.2 (http://www.R-project.org) 
(7): forced expiratory volume in 1s (FEV1), peak work rate (Wpeak), peak oxygen uptake (VO2peak), 
age at CPET, the breathing reserve index at peak exercise (VEpeak/MVVpred), ventilatory equivalent 
for oxygen at peak exercise (VE/VO2), ventilatory equivalent for carbon dioxide at peak exercise 
(VE/VCO2), body mass index (BMI), sex, chronic Pseudomonas aeruginosa colonization, pancreatic 
insufficiency and cystic fibrosis-related diabetes (CFRD). The separation between clusters was 
calculated using the Euclidean distance, and the agglomeration procedure was done according to 
Ward’s minimum variance method. The optimal number of clusters was determined based on the 
majority rule for indices using the R-package “NbClust” (8). In the next step, the relevance of each 
parameter used for clustering was investigated. Therefore, an unsupervised Random Forests analysis 
approach was chosen where the data is classified without a priori classification specifications (9). For 
each variable, an importance value is reported. The variables are ranked within a variable importance 
plot according to their importance. 
Based on the Forest plot, the parameters for clustering were selected. Given that some of the 
input parameters were correlated, principal component analysis (PCA) was performed as a dimension 
reduction procedure. The resulting linear combination corresponds to a principal component (PC) (10). 
The number of PC were selected that would explain at least 95% of overall variation in data. Finally, 
these components were used as input parameters for Ward’s hierarchical clustering, as described above. 
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Results of Ward’s hierarchical clustering 
All CPET parameters and FEV1 had a high variable importance to define clusters, as indicated by the 
Forest plot (Figure 4 in the original publication). However, the binary coded variables (sex, chronic 
Pseudomonas aeruginosa colonization, pancreatic insufficiency and CFRD were less important. Based 
on the Forest plot, the eight continuous variables (FEV1, BMI, Wpeak, age at CPET, VO2peak, 
VEpeak/MVVpred, VE/VO2peak, and VE/VCO2peak) were introduced into the PCA, and five 
orthogonal factors (=principal components) explained more than 95% of variance (Table E12). Ward’s 
hierarchical clustering was feasible, and the optimal number of clusters was four. The heat map 
containing the dendogram obtained using clustering of the five PCs is shown in Figure E2. The 
characteristics of the four clusters identified containing n=207, n=130, n=54 and n=33 patients is given 
in Table 3 in the original publication. 
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Table E2 Comparison of genotype, lung function, comorbidities and cardiopulmonary exercise testing 
data among survivors and cases
Variables Survivors
(N=359)
Death/LTx
(N=74)
P-value
Age (years) 14.2 (12.4, 17.7) 17.1 (14.0, 22.5) <0.001
Sex, N female (%) 146/359 (41) 38/74 (50) 0.091
BMI (z-score) -0.55±0.90 -1.39±1.14 <0.001
Genotype
CFTR, both alleles from classes 
I-III, N (%)
271/359 (76) 44/74 (59)
CFTR, at least one allele from 
classes IV-V, N (%)
21/359 (6) 1/74 (1)
CFTR, at least one allele 
unknown/not available, N (%)
67/359 (19) 29/74 (39)
<0.001#
F508del homozygous, N (%) 167/359 (47) 34/74 (46)
F508del heterozygous, N (%) 137/359 (38) 19/74 (26)
Others, N (%) 36/359 (10) 9/74 (12)
Unknown, N (%) 19/359 (5) 12/74 (16)
0.003$
Lung function
FEV1 (% predicted) 80.5 (67.3, 91.4) 45.6 (34.2, 55.5) <0.001
FVC (% predicted) 88.7±14.6 65.0±16.3 <0.001
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Comorbidities
Chronic Pseudomonas 
aeruginosa infection (%)
233/356 (65) 62/68 (91) <0.001
Pancreatic insufficiency (%) 331/357 (93) 74/74 (100) 0.017
CFRD (%) 24/357 (7) 10/69 (14) 0.029
CPET parameters
VO2peak (% predicted) 86.7±18.3 59.2±19.1 <0.001
Wpeak (% predicted) 94.1 (80.9, 107.9) 66.3 (53.0, 81.1) <0.001
VE/VO2peak 38.0 (34.6, 43.4) 40.2 (35.6, 48.5) 0.013
VE/VCO2peak 33.0 (29.6, 36.9) 35.7 (31.2, 42.1) 0.001
VEpeak/MVVpred 0.88 (0.76, 1.06) 1.06 (0.94, 1.20) <0.001
SpO2peak (%) 96.0 (94.0, 98.0) 93.0 (88.0, 95.0) <0.001
∆VE/∆VCO2 slope* 29.5 (26.5, 32.9) 30.4 (27.5, 34.8) 0.193
Data are mean±SD, median (interquartile range) or N (%). BMI, body mass index; CFRD, cystic fibrosis-related 
diabetes; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume in 1s; 
VEpeak/MVVpred, breathing reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; 
VE/VO2peak, ventilatory equivalent for oxygen; ∆VE/∆VCO2 slope, minute ventilation-carbon dioxide 
production relationship slope; SpO2peak, oxygen saturation at peak exercise; VO2peak, peak oxygen uptake; 
Wpeak, peak work rate. * Data only available for 218 patients (24 death/LTx cases). Comparisons between 
groups were done using the independent t-test; Mann-Whitney-U test or the Chi-square test, as appropriate. 
# If Chi-square statistics is calculated for patients with known genotype by excluding patients with at least one 
“unknown; non-available” CFTR allele, no difference in genotype is observed between the groups (P=0.21).
$If Chi-square statistics is calculated for patients with known genotype by excluding the “unknown”, no 
difference in genotype is observed between the groups (P=0.33).
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Table E3. Patients´ characteristics separated by study center. 
Center
N
Mean Follow-up 
(years)
Death / LTx
N (%)
Age 
(years)
FEV1
(% predicted)
BMI
(z-score)
Chronic PA 
(%)
PI 
(%)
CFRD
(%)
Chicago 44 9.5±1.7 3 (7) 16.3±3.6 78.4±20.1 -0.45±1.19 79.5 93.2 2.3
Gothenburg 24 10.9±1.6 0 (0) 25.6±5.9 84.7±21.6 -0.36±0.83 54.2 79.2 20.8
London 24 6.8±2.3 6 (25) 13.4±1.8 70.4±21.3 -0.54±0.68 95.8 91.7 4.2
Montreal 18 7.4±0.9 1 (6) 13.2±1.4 81.0±19.3 -0.58±0.65 38.9 100.0 11.1
Paris 44 7.8±3.4 14 (32) 15.0±3.0 68.4±24.2 -0.90±0.99 94.3 92.7 10.8
Swiss 37 12.3±3.0 7 (19) 21.8±5.4 61.4±20.4 -1.51±1.04 89.2 97.3 13.5
Sydney 28 7.4±3.2 15 (54) 27.3±6.9 53.1±22.0 -0.90±0.83 92.9 92.9 25.0
Toronto 72 9.7±2.1 4 (6) 12.1±1.7 83.8±15.4 -0.35±0.94 18.1 88.9 6.9
Utrecht 74 7.0±1.4 7 (9) 13.3±1.1 73.3±17.6 -0.81±0.80 95.9 100.0 2.7
Würzburg 68 9.9±2.9 17 (25) 18.1±6.1 72.9±23.5 -0.66±1.11 61.2 97.1 3.0
Total 433 8.9±2.9 (0.1; 14.0) 74 (17) 16.6±6.1 (10.0; 44.5) 73.4±21.8 (1.7; 123.4) -0.70±1.0 (-4.53; 1.89) 69.6 94.0 8.0
Data are mean±standard deviation or number (percentage) or ranges of study sample. BMI, body mass index; CFRD, cystic fibrosis-
related diabetes; LTx, lung transplantation; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; PI, Pancreatic 
insufficiency. Death/LTx rates were significantly different between centers (Chi-squared test, P<0.001).
Table E4 Cardiopulmonary exercise testing variables separated by study center.
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Center
N
VO2peak
(% 
predicted)
Wpeak
(% 
predicted)
VE/VO2peak VE/VCO2peak VEpeak/MVVpred
(%)
SpO2peak
(%)
∆VE/∆VCO2slope
Chicago 44 100.0±25.3 96.8±22.7 41.3±7.2 35.3±5.7 98.1±23.7 93.6±2.6 33.8±7.6
Gothenburg 24 91.4±20.1 117.0±24.8 41.3±5.8 31.8±3.4 93.6± 2.0 95.1±2.0 27.2±2.8
London 24 76.7±15.3 91.5±20.0 39.1±7.1 33.3±6.6 95.0±24.8 96.6±3.6 ---
Montreal 18 94.5±20.8 85.2±13.5 35.0±3.8 29.6±1.7 86.8±24.7 96.2±2.4 ---
Paris 44 68.5±19.4 73.0±18.8 46.5±7.7 40.6±7.7 101.6±32.7 93.6±3.2 ---
Swiss 37 77.4±17.1 102.7±20.9 42.4±6.7 37.4±5.2 110.5±26.5 89.5±4.6 31.4±7.0
Sydney 28 54.1±18.8 64.9±24.8 37.2±8.5 31.6±6.8 80.1±21.2 92.7±4.9 ---
Toronto 72 90.0±14.2 84.7±13.1 40.9±4.9 35.8±3.6 98.2±21.6 98.9±1.3 30.3±3.5
Utrecht 74 81.8±15.0 98.3±20.0 36.8±6.9 31.7±5.4 91,5±19.4 96.0±3.0 ---
Würzburg 68 79.7±17.8 95.6±21.9 35.1±5.7 30.7±4.8 83.4±22.9 94.7±5.0 27.2±3.5
Total
433
82.0±21.1 
(23.3, 151.2)
91.2±23.3 
(17.3, 196.8)
39.5±7.3 
(13.3, 69.2)
34.0±6.2 
(11.1, 68.4)
94.0±25.3 
(23.5, 206.1)
95.1±4.3 
(74, 100)
30.2±5.7 
(19.7, 72.0)
Data are mean±standard deviation or number (percentage) or ranges of study sample. ∆VE/∆VCO2slope, minute ventilation-carbon dioxide 
production relationship slope; VEpeak/MVVpred, breathing reserve index (MVV was calculated as FEV1*35); VE/VCO2, ventilatory equivalent for 
carbon dioxide; VE/VO2, ventilatory equivalent for oxygen; SpO2peak, oxygen saturation at peak exercise; VO2peak, peak oxygen uptake; Wpeak, 
peak work rate.
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Table E5. Cox proportional hazards regression predictors of death or lung transplantation (LTx). Univariate analyses using a random 
effects model with study center adjustment. 
Variable Total N Hazard ratio (exp(B)) P-value Interpretation
Female Sex 433 1.490 (0.937; 2.370) 0.092 Female sex (n=184) not significantly worse outcome 
than male sex (n=249) 
CFRD 426 1.649 (0.819; 3.319) 0.161 CFRD (n=34) not significantly worse outcome than 
no CFRD (n=392) 
Chronic Pseudomonas aeruginosa 
infection
424 4.697 (1.889; 11.678) 0.001 Chronic PA (n=295) significantly worse outcome 
than no PA (n=129) 
Age at CPET (years) 433 1.009 (0.969; 1.051) 0.661 Higher age at CPET not significantly associated with 
unfavorable or favorable outcome
FEV1 (% predicted) 431 0.937 (0.924; 0.950) 0.001 Higher FEV1 significantly associated with better 
outcome
BMI (z-score) 433 0.534 (0.438; 0.651) <0.001 Higher BMI significantly associated with better 
outcome
VO2peak (% predicted) 433 0.935 (0.924; 0.947) <0.001 Higher VO2peak significantly associated with better 
outcome
Wpeak (% predicted) 426 0.944 (0.932; 0.956) <0.001 Higher Wpeak significantly associated with better 
outcome
VE/VO2peak 433 1.084 (1.050; 1.119) <0.001 Higher VE/VO2 significantly associated with 
unfavorable outcome
VE/VCO2peak 433 1.125 (1.085; 1.167) <0.001 Higher VE/VCO2 significantly associated with 
unfavorable outcome
VEpeak/MVVpred 432 12.656 (5.825; 27.498) <0.001 Higher VEpeak/MVVpred significantly associated 
with unfavorable outcome
SpO2peak (%) 393 0.866 (0.830; 0.904) <0.001 Higher SpO2peak significantly associated with better 
outcome
∆VE/∆VCO2 slope 218 1.128 (1.072; 1.186) <0.001 Higher ∆VE/∆VCO2 slope significantly associated 
with unfavorable outcome
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; VEpeak/MVVpred, breathing 
reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for oxygen; ∆VE/∆VCO2 slope, minute ventilation-
carbon dioxide production relationship slope; SpO2peak, oxygen saturation at peak exercise; VO2peak, peak oxygen uptake; Wpeak, peak work rate. Sex is coded as 
0=male and 1=female. Effect estimates for pancreatic insufficiency could not be computed because there were no cases (death/LTx) that were pancreatic sufficient.
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Table E6. Cox proportional hazards regression predictors of death or lung transplantation (LTx). Univariate analyses using a random 
effects model without study center adjustment. 
Variable Total N Hazard ratio (95% CI) P-value Interpretation
Female Sex 433 1.481 (0.939; 2.336) 0.092 Female sex (n=184) not significantly worse than male sex 
(n=249) 
CFRD 426 1.922 (0.983; 3.759) 0.056 CFRD (n=34) not significantly worse than no CFRD 
(n=392) 
Chronic Pseudomonas aeruginosa 424 5.263 (2.275; 12.173) <0.001 Chronic PA (n=295) significantly worse than no PA (n=129) 
Age at CPET (years) 433 1.031 (1.000; 1.064) 0.053 Higher age at CPET not significantly associated with 
unfavorable or favorable outcome
FEV1 (% predicted) 431 0.936 (0.924; 0.948) 0.001 Higher FEV1 significantly associated with better outcome
BMI (z-score) 433 0.546 (0.454; 0.655) <0.001 Higher BMI significantly associated with better outcome
VO2peak (%predicted) 433 0.935 (0.924; 0.947) <0.001 Higher VO2peak significantly associated with better 
outcome
Wpeak (%predicted) 426 0.941 (0.930; 0.953) <0.001 Higher Wpeak significantly associated with better outcome
VE/VO2peak 433 1.059 (1.028; 1.092) <0.001 Higher VE/VO2 significantly associated with unfavorable 
outcome
VE/VCO2peak 433 1.095 (1.058; 1.134) <0.001 Higher VE/VCO2 significantly associated with unfavorable 
outcome
VEpeak/MVVpred 432 6.188 (2.994; 12.791) <0.001 Higher VEpeak/MVVpred significantly associated with 
unfavorable outcome
SpO2peak (%) 393 0.878 (0.845; 0.912) <0.001 Higher SpO2peak significantly associated with better 
outcome
∆VE/∆VCO2 slope 218 1.108 (1.055-1.164) <0.001 Higher ∆VE/∆VCO2 slope significantly associated with 
unfavorable outcome
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; SpO2peak, 
oxygen saturation at peak exercise; VEpeak/MVVpred, breathing reserve index (MVV was calculated as FEV1*35); VE/VCO2peak, ventilatory 
equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for oxygen; ∆VE/∆VCO2 slope, minute ventilation -carbon dioxide production 
relationship slope; VO2peak, peak oxygen uptake; Wpeak, peak work rate. Sex is coded as 0=male and 1=female.
Table E7. Cox proportional hazards regression predictors of death or lung transplantation (LTx). Univariable analyses using a random 
effects model with study center adjustment in a subsample of patients with advanced lung disease (FEV1  40% predicted). 
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Variable Total N Hazard ratio (exp(B)) P-value Interpretation
Female Sex 39 1.023 (0.408; 2.564) 0.961 Female sex not significantly worse outcome than male sex 
CFRD 36 1.079 (0.364; 3.120) 0.891 CFRD not significantly worse outcome than no CFRD 
Chronic Pseudomonas aeruginosa 
infection 37 1.760 (0.232; 13.350) 0.584
Chronic PA not significantly worse outcome than no 
PA 
Age at CPET (years) 39 0.910 (0.844; 0.981) 0.014 Higher age at CPET significantly associated with favorable outcome
FEV1 (% predicted) 39 0.964 (0.891; 1.043)
0.364 Higher FEV1 not significantly associated with better 
outcome
BMI (z-score) 39 0.923 (0.669; 1.273) 0.624 Higher BMI not significantly associated with better outcome
VO2peak (% predicted) 39 0.962 (0.931; 0.994) 0.019
Higher VO2peak significantly associated with better 
outcome
Wpeak (% predicted) 39 0.963 (0.936; 0.990) 0.007 Higher Wpeak significantly associated with better outcome
VE/VO2peak 39
1.081 (1.03; 1.114) 0.002 Higher VE/VO2 at peak exercise significantly associated with unfavorable outcome
VE/VCO2peak 39 1.092 (1.033; 1.154) 0.002
Higher VE/VCO2 at peak exercise significantly 
associated with unfavorable outcome
VEpeak/MVVpred 39 0.556 (0.141; 2.191) 0.401 Higher VEpeak/MVVpred not significantly associated with unfavorable outcome
SpO2peak (%) 32
0.939 (0.863; 1.022) 0.147 Higher SpO2peak not significantly associated with better outcome
∆VE/∆VCO2 slope 14 1.042 (0.977; 1.113) 0.208
Higher ∆VE/∆VCO2 slope not significantly 
associated with unfavorable outcome
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; 
VEpeak/MVVpred, breathing reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for 
oxygen; ∆VE/∆VCO2 slope, minute ventilation-carbon dioxide production
Table E8. Cox proportional hazards regression predictors of death or lung transplantation (LTx). Univariable analyses using a random 
effects model without study center adjustment in a subsample of patients with advanced lung disease (FEV1  40% predicted).
Variable Total N Hazard ratio (exp(B)) P-value Interpretation
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Female Sex 39 0.894 (0.385; 2.076) 0.794 Female sex not significantly worse outcome than male sex 
CFRD 36 1.079 (0.364; 3.199) 0.891 CFRD not significantly worse outcome than no CFRD 
Chronic Pseudomonas aeruginosa 
infection 37 1.833 (0.246; 13.637) 0.554
Chronic PA not significantly worse outcome than no 
PA 
Age at CPET (years) 39 0.954 (0.900; 1.011) 0.114 Higher age at CPET not significantly associated with favorable or unfavorable outcome
FEV1 (% predicted) 39 0.952 (0.881; 1.031) 0.228
Higher FEV1 not significantly associated with better 
outcome
BMI (z-score) 39 0.982 (0.737; 1.309) 0.902 Higher BMI not significantly associated with better outcome
VO2peak (% predicted) 39 0.961 (0.931; 0.992) 0.014
Higher VO2peak significantly associated with better 
outcome
Wpeak (% predicted) 38 0.963 (0.938; 0.989) 0.006 Higher Wpeak significantly associated with better outcome
VE/VO2peak 39 1.082 (1.030; 1.137) 0.002
Higher VE/VO2 at peak exercise significantly 
associated with unfavorable outcome
VE/VCO2peak 39 1.092 (1.035; 1.153) 0.001
Higher VE/VCO2 at peak exercise significantly 
associated with unfavorable outcome
VEpeak/MVVpred 39 0.860 (0.265; 2.791) 0.801 Higher VEpeak/MVVpred not significantly associated with unfavorable outcome
SpO2peak (%) 32 0.966 (0.899; 1.038) 0.350
Higher SpO2peak not significantly associated with 
better outcome
∆VE/∆VCO2 slope 14 1.043 (0.977; 1.112) 0.208
Higher ∆VE/∆VCO2 slope not significantly 
associated with unfavorable outcome
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; 
VEpeak/MVVpred, breathing reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for 
oxygen; ∆VE/∆VCO2 slope, minute ventilation-carbon dioxide production
Table E9. Cox proportional hazards regression predictors of death or lung transplantation (LTx). Univariable analyses using a random 
effects model with study center adjustment restricted to 2-year follow-up data.
Variable Total N Hazard ratio (exp(B)) P-value Interpretation
Female Sex 433 1.331 (0.380; 4.658) 0.654 Female sex not significantly worse outcome than male sex 
Page 45 of 53  AJRCCM Articles in Press. Published on 15-October-2018 as 10.1164/rccm.201806-1110OC 
 Copyright © 2018 by the American Thoracic Society 
18
CFRD 426 3.120 (0.625; 16.395) 0.163 CFRD not significantly worse outcome than no CFRD 
Chronic Pseudomonas aeruginosa 
infection 424 - -
All death/LTx cases were chronically infected with 
Pseudomonas aeruginosa. Hazard ratio could 
therefore not be calculated.
Age at CPET (years) 433 1.008 (0.900; 1.128) 0.895 Higher age at CPET not significantly associated with favorable or unfavorable outcome
FEV1 (% predicted) 431 0.916 (0.877; 0.957) <0.001
Higher FEV1 significantly associated with better 
outcome
BMI (z-score) 433 0.380 (0.218; 0.664) 0.001 Higher BMI significantly associated with better outcome
VO2peak (% predicted) 433 0.921 (0.889; 0.955) <0.001
Higher VO2peak significantly associated with better 
outcome
Wpeak (% predicted) 426 0.934 (0.908; 0.961) <0.001 Higher Wpeak significantly associated with better outcome
VE/VO2peak 433 1.151 (1.075; 1.231) <0.001
Higher VE/VO2 at peak exercise significantly 
associated with unfavorable outcome
VE/VCO2peak 433 1.170 (1.094; 1.250) <0.001
Higher VE/VCO2 at peak exercise significantly 
associated with unfavorable outcome
VEpeak/MVVpred 432 16.780 (3.092; 91.064) 0.001 Higher VEpeak/MVVpred significantly associated with unfavorable outcome
SpO2peak (%) 393 0.822 (0.733; 0.921) 0.001
Higher SpO2peak significantly associated with better 
outcome
∆VE/∆VCO2 slope 218 0.768 (0.437; 1.348) 0.358
Higher ∆VE/∆VCO2 slope not significantly 
associated with unfavorable outcome
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; 
VEpeak/MVVpred, breathing reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for 
oxygen; ∆VE/∆VCO2 slope, minute ventilation-carbon dioxide production
Table E10. Cox proportional hazards regression predictors of death or lung transplantation (LTx). Univariable analyses using a random 
effects model without study center adjustment restricted to 2-year follow-up data.
Variable Total N Hazard ratio (exp(B)) P-value Interpretation
Female Sex 433 1.367 (0.396; 4.724) 0.621 Female sex not significantly worse outcome than male sex 
CFRD 426 3.871 (0.781; 19.179) 0.097 CFRD not significantly worse outcome than no 
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CFRD 
Chronic Pseudomonas aeruginosa 
infection 424 - -
All death/LTx cases were chronically infected with 
Pseudomonas aeruginosa. Hazard ratio could 
therefore not be calculated.
Age at CPET (years) 433 1.021 (0.932; 1.118) 0.657 Higher age at CPET not significantly associated with favorable or unfavorable outcome
FEV1 (% predicted) 431 0.914 (0.875; 0.955) <0.001
Higher FEV1 significantly associated with better 
outcome
BMI (z-score) 433 0.440 (0.280; 0.691) <0.001 Higher BMI significantly associated with better outcome
VO2peak (% predicted) 433 0.921 (0.889; 0.955) <0.001
Higher VO2peak significantly associated with better 
outcome
Wpeak (% predicted) 426 0.936 (0.913; 0.960) <0.001 Higher Wpeak significantly associated with better outcome
VE/VO2peak 433 1.160 (1.084; 1.240) <0.001
Higher VE/VO2 at peak exercise significantly 
associated with unfavorable outcome
VE/VCO2peak 433 1.170 (1.094; 1.250) <0.001
Higher VE/VCO2 at peak exercise significantly 
associated with unfavorable outcome
VEpeak/MVVpred 432 23.22 (4.565; 118.127) <0.001 Higher VEpeak/MVVpred significantly associated with unfavorable outcome
SpO2peak (%) 393 0.852 (0.778; 0.934) 0.001
Higher SpO2peak significantly associated with better 
outcome
∆VE/∆VCO2 slope 218 0.768 (0.437; 1.348) 0.358
Higher ∆VE/∆VCO2 slope not significantly 
associated with unfavorable outcome
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1s; PA, Pseudomonas aeruginosa; 
VEpeak/MVVpred, breathing reserve index; VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for 
oxygen; ∆VE/∆VCO2 slope, minute ventilation-carbon dioxide production
Table E11 Cystic fibrosis risk groups based on three different VO2peak groups according to Nixon et al. (11)
VO2peak ≥82 predicted
N=239 (group 1)
VO2peak 59-81 predicted
N=133 (group 2)
VO2peak ≤58 predicted
N=61 (group 3)
P-value
Exposure Variable
Female Sex 98 (41) 57 (43) 29 (48) 0.357
Age at CPET (years) 15.7 ± 5.4 16.8 v 6.0$ 20.0 ± 7.6 < 0.001
BMI (z-score) -0.42 ± 0.83 -0.80 ± 0.93$ -1.59 ± 1.17 < 0.001
CFRD 13 (5)† 13 (10) 8 (13) 0.052
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Chronic Pseudomonas a. colonization 137 (57)† 106 (80)$ 52 (85) < 0.001
FEV1 (% predicted) 84.4 ±15.0*† 65.8 ± 19.7$ 47.1 ± 19.4 < 0.001
FVC (% predicted) 92.9 ± 11.9*† 79.3 ± 16.0$ 63.8 ± 16.2 < 0.001
VO2peak (% predicted) 96.8 ±13.3*† 71.1 ± 5.9$ 47.5 ± 9.8 < 0.001
Wpeak (% predicted) 103.8 ± 19.1*† 82.1 ± 13.1$ 60.2 ± 17.9 < 0.001
VE/VO2peak 38.2 ± 6.2*† 39.9 ± 6.9 43.3 ± 10.4 0.025
VE/VCO2peak 32.7 ± 4.9† 34.7 ± 5.4$ 37.5 ± 9.5 0.004
SpO2peak (%) 96.2 ± 3.5*† 94.5 ± 4.1 91.5 ± 5.7 < 0.001
VEpeak/MVVpred 0.92 ± 0.20 0.96 ± 0.30$ 0.96 ± 0.32 0.601
∆VE/∆VCO2 slope 29.4 ± 4.4 30.5 ± 4.6 36.0 ± 13.9
Outcomes death or LTx
Up to five years’ follow-up 2 (1)*† 10 (8)$ 18 (30) < 0.001
Up to ten years’ follow-up 6 (3)*† 22 (17)$ 37 (61) < 0.001
Entire study period 10 (4)*† 25(19)$ 39 (65) < 0.001
Values are N (percent) or mean±standard deviation. Differences in the distribution of characteristics across phenotypes were assessed using Chi-
squared tests for categorical variables, and Kruskal–Wallis for continuous variables. BMI, body mass index; CFRD, cystic fibrosis-related diabetes; 
FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; SpO2peak, oxygen saturation at peak exercise; VEpeak/MVVpred, breathing 
reserve index (MVV was calculated as FEV1*35); VE/VCO2peak, ventilatory equivalent for carbon dioxide; VE/VO2peak, ventilatory equivalent for 
oxygen; VO2peak, peak oxygen uptake; Wpeak, peak work rate. *Difference between group 1 and 2; †Difference between group 1 and 3; 
$Difference between group 2 and 3 using Chi-squared tests for categorical variables and Kruskal–Wallis, as appropriate. The Bonferroni-
corrected significance level for these tests was 0.017 (overall significance level (0.05) divided by number of tests, which was 3 as we 
compared 4 clusters). If the test passed the significance level, a sign is shown in the table. Data for ∆VE/∆VCO2 slope was only available for a 
subset of patients (group 1=143; group 2=60 and group 3=15.
Table E12 Correlation of the original continues variables with the five main components derived from the prinicpal component analysis
PC  1 PC  2 PC  3 PC  4 PC 5
Age at CPET (years) -0,1536 -0,4674 0,4061 0,7594 -0,0196
FEV1 (% predicted) 0,7597 0,3782 -0,3885 0,2027 -0,1916
BMI (z-score) 0,6162 0,1988 -0,0788 0,2119 0,7227
VO2peak (% predicted) 0,7526 0,4606 0,3293 -0,1013 -0,0568
Wpeak (% predicted) 0,6776 0,3321 0,4841 0,1289 -0,2676
VE/VO2 -0,6188 0,6752 -0,1291 0,3127 -0,0608
Page 48 of 53 AJRCCM Articles in Press. Published on 15-October-2018 as 10.1164/rccm.201806-1110OC 
 Copyright © 2018 by the American Thoracic Society 
21
VE/VCO2 -0,6852 0,6392 -0,1640 0,1904 0,0060
VEpeak/MVVpred -0,5551 0,3556 0,6522 -0,2612 0,2022
CPET, cardiopulmonary exercise test; FEV1, forced expiratory volume in 1s; BMI, body mass index; PC, Principal Component; 
VEpeak/MVVpred, breathing reserve index (MVV was calculated as FEV1*35); VE/VCO2peak, ventilatory equivalent for carbon 
dioxide; VE/VO2peak, ventilatory equivalent for oxygen; VO2peak, peak oxygen uptake; Wpeak, peak work rate. Five orthogonal factors 
extracted explained >95% of variance.
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Figure legends
Figure E1. Kaplan-Meier survival curve for three different Wpeak groups. Wpeak, peak work rate. 
Figure E2. Heat map representing hierarchical Ward’s clustering. The left color bar denotes individual 
subject grouping and their related cluster indicated by different colors: cluster one (Cyan, n=207), 
cluster two (green, n=130), cluster three (red n=54) and cluster four (purple, n=33). Column on the 
right: colors correspond to the clusters reported on the left bar, and for each cluster the percent of the 
main outcome (deaths or LTx) is reported. Horizontal bar denotes the values from each principal 
component (PC): dark blue represents values below the mean, white represents the mean value, and 
dark red represents values above the mean.
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 Figure E1. Kaplan-Meier survival curve for three different Wpeak groups. Wpeak, peak work rate. 
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 Figure E2. Heat map representing hierarchical Ward’s clustering. The left color bar denotes individual subject 
grouping and their related cluster indicated by different colors: cluster one (Cyan, n=207), cluster two 
(green, n=130), cluster three (red n=54) and cluster four (purple, n=33). Column on the right: colors 
correspond to the clusters reported on the left bar, and for each cluster the percent of the main outcome 
(deaths or LTx) is reported. Horizontal bar denotes the values from each principal component (PC): dark 
blue represents values below the mean, white represents the mean value, and dark red represents values 
above the mean. 
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